ArticleBMC ophthalmology2026
Silicone oil-associated visual loss in macula-on rhegmatogenous retinal detachment - does the tamponade duration affect the outcome?
Article in BMC ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSilicone oil (SO)-associated unexplained visual loss (UVL) is a serious phenomenon after pars-plana-vitrectomy (ppV). Due to reports of UVL, we started earlier SO removal (SOR) in macula-on rhegmatogenous retinal detachments (RRD) in 2020. This study aims to investigate the effect of a shorter (≤ 60 days) compared to a long-term (> 60 days) SO tamponade.
methodsAll consecutive macula-on RRDs (2020-2025) treated with ppV were retrospectively analysed comparing eyes with short-term vs. long-term SO tamponade regarding best corrected visual acuity (BCVA), intraocular pressure (IOP), central foveal thickness (CFT) and the incidence of UVL. Inclusion criteria were a detailed clinical documentation and a minimum follow-up (FU) of 2 months after SOR. If available, CFT values were analysed before, during, and after SO.
resultsOverall, 37 eyes received ppV with SO for macula-on RRD. In 25 eyes (68%), SOR was performed within 60 days. Due to organizational issues (Covid, capacity) or patient-related factors (cancellation, illness), SO remained for longer than 60 days in 12 eyes (32%). Primary reattachment was achieved in all eyes. In the short-term group SOR was after 36 days (SD 13.4) and in the long-term cohort after 92 days (SD 20.9). UVL (≥ 2 Snellen lines BCVA loss without correlate) was significantly more common in the long-term (5/12) than in the short-term SO group (0/25) (p = 0,002). There were no differences in intra -and postoperative parameters (cut-suture time, IOP, CFT). Eyes with long-term SO had a final BCVA of logMAR 0.5 (SD 0.34) compared to a preoperative BCVA of logMAR 0.3 (SD 0.21). In eyes with short-term SO the BCVA before surgery (0.3; SD 0.29) and after SOR (0.3; SD 0.28) were comparable. The final BCVA after SOR was significantly better after short-term than after long-term tamponade (p = 0.033).
conclusionEyes with a shorter SO tamponade (≤ 60 days) had better postoperative BCVA, while 42% in the long-term group (> 60 days) experienced UVL Taking into account the limitations of our small cohort, the risk of UVL during SO tamponade should be considered, especially in macula-on cases. Currently, an early SOR is the only modifiable surgical approach to address this adverse event.
trial registrationThe study was approved by the local ethics committee on 31st of October 2025 (Ethikkommission der Universität Regensburg, Votum 254385104) and was conducted in accordance with the ethical standards of the Declaration of Helsinki.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.